Drug Profile


Alternative Names: WAS 4304; WAS 4351

Latest Information Update: 08 Oct 2001

Price : $50

At a glance

  • Originator Wasserman-SEEFT
  • Class Antiulcers
  • Mechanism of Action Beta 3 adrenergic receptor agonists; Gastrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetes mellitus; Obesity
  • Discontinued Peptic ulcer

Most Recent Events

  • 08 Oct 2001 No-Development-Reported for Obesity in Spain (PO)
  • 08 Oct 2001 No-Development-Reported for Diabetes mellitus in Spain (PO)
  • 09 Nov 1999 Trecadrine is being investigated for use in Diabetes and Obesity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top